HER2/neu overexpression or amplification is more frequently found in non-endometrioid endometrial carcinoma (18–80%) [13] than in grade 2 and 3 endometrioid carcinoma (10–30%) [7, 9, 10] and has been associated with adverse prognostic parameters including advanced stage, high histologic grade, and low overall survival [9, 13]. Here, ERBB2 is linked to endometrioid adenocarcinoma.